ログイン

LMR 13

LMR 13
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Amount of fixative used has been 10 to 25 times the volume of tissue to be fixed. Recently, the maximum effectiveness of fixation is noted to be ? times the tissue volume

    20

  • 2

    Recommended ratio of fluid to tissue volume for DECALCIFICATION is

    20 to 1

  • 3

    Recommended ratio of fluid to tissue volume for ? is 20 to 1

    DECALCIFICATION

  • 4

    Amount of dehydrating agent should not be ? the volume of tissue

    less than 10 times

  • 5

    : Low grade to high grade alcohol

    Dehydration

  • 6

    Absence of water:

    WHITE anhydrous copper sulfate

  • 7

    Presence of water:

    BLUE anhydrous copper sulfate

  • 8

    Clearing:

    Dealcoholization

  • 9

    : Dealcoholization

    Clearing

  • 10

    Most rapid embedding technique:

    Vacuum embedding

  • 11

    Automated tissue processor:

    fidc Fix, dehydrate, clear, and infiltrate

  • 12

    ? processor: Fix, dehydrate, clear, and infiltrate

    Automated tissue

  • 13

    Histochemical demonstration of ENZYMES:

    FROZEN SECTION

  • 14

    is the most commonly used fluorochrome to demonstrate DNA and RNA in fresh or fixed tissues

    ACRIDINE ORANGE

  • 15

    ? method: Calcium salts = black

    Von Kossa’s silver nitrate

  • 16

    Von Kossa’s silver nitrate method: ? = black

    Calcium salts

  • 17

    Von Kossa’s silver nitrate method: Calcium salts = ?

    black

  • 18

    Red chromogen for peroxidases:

    Aminoethylcarbazole (AEC)

  • 19

    Brown chromogen for peroxidases:

    Diaminobenzidine (DAB)

  • 20

    ?color chromogen for peroxidases: Diaminobenzidine (DAB)

    Brown

  • 21

    ? color chromogen for peroxidases: Aminoethylcarbazole (AEC)

    Red

  • 22

    Administrative investigation:

    2 members of board + 1 legal officer

  • 23

    Policies and guidelines for Med Tech Education:

    CMO no. 14 s. 2006

  • 24

    Accreditation of clinical lab for training MT interns:

    CMO no. 6 s. 2008

  • 25

    STAT, STATIM:

    Immediately

  • 26

    : Immediately

    STAT, STATIM

  • 27

    Biodegradable wastes: color bag

    Green bag

  • 28

    ? wastes: Green bag

    Biodegradable

  • 29

    Urine for routine urinalysis: ? ml urine (? capacity)

    10 to 15 ( 50 mlcontainer capacity)

  • 30

    Urine for drug testing: ? ml (?-container capacity)

    30 to 45 , (60 ml-container capacity)

  • 31

    Urine for cytology: ? ml urine (Gregorios)

    at least 50

  • 32

    Venipucture: ? degree angle

    15 to 30 degree angle

  • 33

    Arterial puncture: ? degree angle (90 degrees for femoral artery)

    45 to 60

  • 34

    Arterial puncture: 45 to 60 degree angle (90 degrees for ?)

    femoral artery

  • 35

    Arterial puncture: 45 to 60 degree angle (? degrees for femoral artery)

    90

  • 36

    ?: 45 to 60 degree angle (90 degrees for femoral artery)

    Arterial puncture

  • 37

    : 15 to 30 degree angle

    Venipucture

  • 38

    Before blood is collected from the radial artery in the wrist, one should do a ? to determine whether the ulnar artery can provide collateral circulation to the hand after the radial artery puncture

    MODIFIED ALLEN TEST

  • 39

    ? collection: eliminates multiple phlebotomies and surgical situations

    Central Venous Assess (CVA)

  • 40

    ) ml of blood must be drawn and discarded to eliminate contaminants

    Five (5

  • 41

    is not recommended for bacteriology (organisms can contaminate specimen)

    CVA

  • 42

    Order of draw from CATHETER LINES: First ? ml blood is discarded THEN, blood culture, anticoagulated tubes and clot tubes.

    3 to 5

  • 43

    Donor bleeding: ? degree angle to the skin, make a quick clean puncture; once in the skin, reduce the angle of the needle to about 10 to 20 degrees

    45 degree angle

  • 44

    Donor bleeding: 45 degree angle to the skin, make a quick clean puncture; once in the skin, reduce the angle of the needle to about ?degrees

    10 to 20

  • 45

    Anaerobic and require ICE slurry (immediate cooling):

    Lactic acid, ammonia, blood gas

  • 46

    Anaerobic and require ICE slurry (immediate cooling): Lactic acid, ammonia, blood gas (if not analyzed within ? min = ↓ pH, and po2),

    30

  • 47

    Anaerobic and require ICE slurry (immediate cooling): Lactic acid, ammonia, blood gas (if not analyzed within 30 min = pH, and po2),

  • 48

    (heparinized whole blood if not analyzed within 30 min)

    iCa+2

  • 49

    : evaluates hypoglycemia and continuous assessment of beta cell function

    C-Peptide test

  • 50

    Increased C-peptide:

    Insulinoma, type 2 DM, ingestion of hypoglycemic drugs

  • 51

    ? C-peptide: Insulinoma, type 2 DM, ingestion of hypoglycemic drugs

    Increased

  • 52

    Decreased C-peptide:

    Type 1 DM

  • 53

    ? C-peptide: Type 1 DM

    Decreased

  • 54

    Colorimetric method for Triglycerides:

    van Handel and Zilversmith

  • 55

    Colorimetric method for ?: van Handel and Zilversmith

    Triglycerides

  • 56

    CDC reference method:

    Modified van Handel and Zilversmith

  • 57

    ? method for Triglycerides: Hantzch condensation

    Fluorometric

  • 58

    Fluorometric method for ?: Hantzch condensation

    Triglycerides

  • 59

    Fluorometric method for Triglycerides:

    Hantzch condensation

  • 60

    Largest and least dense:

    CHYLOMICRONS

  • 61

    Smallest but the most dense:

    HDL

  • 62

    Found in obstructive jaundice and LCAT deficiency:

    Lipoprotein X

  • 63

    Found in ?and ? deficiency: Lipoprotein X

    obstructive jaundice and LCAT deficiency

  • 64

    Floating beta lipoprotein:

    β-VLDL

  • 65

    ? beta lipoprotein: β-VLDL

    Floating

  • 66

    Sinking pre-beta lipoprotein:

    Lp (a)

  • 67

    ? lipoprotein: Lp (a)

    Sinking pre-beta

  • 68

    Triglycerides, LDLc: FASTING

    12 to 14 hours

  • 69

    : FASTING 12 to 14 hours

    Triglycerides, LDLc

  • 70

    Formula for LDLc:

    Total cholesterol – HDL – VLDL

  • 71

    Friedewald VLDLc (mmol/L):

    Triglycerides/2.175

  • 72

    De Long VLDLc (mmol/L):

    Triglycerides/2.825

  • 73

    Friedewald VLDLc (mg/dL):

    Triglycerides/5

  • 74

    De Long VLDLc (mg/dL):

    Triglycerides/6.5

  • 75

    ONE-STEP direct method for cholesterol:

    LIEBERMANN-BURCHARDT (L-B)

  • 76

    One-step method for cholesterol: Colorimetry (?)

    Pearson, Stern and MacGavack

  • 77

    Two-step method for cholesterol: C + Extraction (?)

    Bloors

  • 78

    Three-step method for cholesterol: C+ E + Saponification (?)

    Abell-Kendall

  • 79

    Four-step method for cholesterol: C + E + S + Precipitation (?)

    Schoenheimer, Sperry, Parekh and Jung

  • 80

    CDC reference method for cholesterol:

    Abell, Levy and Brodie method

  • 81

    Modification of the ? method continues as the REFERENCE METHOD for cholesterol used by the CDC (Henry)

    ABELL-KENDALL

  • 82

    Modification of the ABELL-KENDALL method continues as the ? METHOD for cholesterol used by the CDC (Henry)

    REFERENCE

  • 83

    Modification of the ABELL-KENDALL method continues as the REFERENCE METHOD for cholesterol used by the ? (Henry)

    CDC

  • 84

    : HDL is abnormal and significantly reduced

    TANGIER’S DISEASE

  • 85

    Activated at cold temperature:

    Factors VII and XI (seven, eleven)

  • 86

    Labile factors, decrease on storage:

    Factors V and VIII (five, eight

  • 87

    ? tube: 11.5 cm long, 3 mm bore

    Wintrobe

  • 88

    Wintrobe tube: ? cm long, ? mm bore

    11.5 cm long, 3 mm bore

  • 89

    Westergren tube: ? cm long, 2.5 mm bore

    30

  • 90

    Westergren tube: 30 cm long, ? mm bore

    2.5

  • 91

    ? tube: 30 cm long, 2.5 mm bore

    Westergren

  • 92

    Capillary tube: ? cm (70-75 mm) long, 1 mm bore (1.2 mm)

    7 to 7.5

  • 93

    Capillary tube: 7 to 7.5 cm (?mm) long, 1 mm bore (1.2 mm)

    70-75

  • 94

    Capillary tube: 7 to 7.5 cm (70-75 mm) long, ? mm bore (? mm)

    1, 1.2

  • 95

    : Centrifuge at 2,000 to 2,300 g for 30 minutes

    Macrohematocrit

  • 96

    Macrohematocrit: Centrifuge at

    2,000 to 2,300 g for 30 minutes

  • 97

    : Centrifuge at 10,000 to 15,000 g for 5 minutes (five minutes)

    Microhematocrit

  • 98

    Microhematocrit: Centrifuge at

    10,000 to 15,000 g for 5 minutes (five minutes)

  • 99

    Normocytic, normochromic:

    GSARAP G6PD SICKLE CELL ANEMIA ACUTE BLOOD LOSS/ LEUKEMIA RENAL DSE APLASTIC ANEMIA PURE RED CELL ANEMIA

  • 100

    GSARAP G6PD SICKLE CELL ANEMIA ACUTE BLOOD LOSS/ LEUKEMIA RENAL DSE APLASTIC ANEMIA PURE RED CELL ANEMIA

    Normocytic, normochromic:

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Amount of fixative used has been 10 to 25 times the volume of tissue to be fixed. Recently, the maximum effectiveness of fixation is noted to be ? times the tissue volume

    20

  • 2

    Recommended ratio of fluid to tissue volume for DECALCIFICATION is

    20 to 1

  • 3

    Recommended ratio of fluid to tissue volume for ? is 20 to 1

    DECALCIFICATION

  • 4

    Amount of dehydrating agent should not be ? the volume of tissue

    less than 10 times

  • 5

    : Low grade to high grade alcohol

    Dehydration

  • 6

    Absence of water:

    WHITE anhydrous copper sulfate

  • 7

    Presence of water:

    BLUE anhydrous copper sulfate

  • 8

    Clearing:

    Dealcoholization

  • 9

    : Dealcoholization

    Clearing

  • 10

    Most rapid embedding technique:

    Vacuum embedding

  • 11

    Automated tissue processor:

    fidc Fix, dehydrate, clear, and infiltrate

  • 12

    ? processor: Fix, dehydrate, clear, and infiltrate

    Automated tissue

  • 13

    Histochemical demonstration of ENZYMES:

    FROZEN SECTION

  • 14

    is the most commonly used fluorochrome to demonstrate DNA and RNA in fresh or fixed tissues

    ACRIDINE ORANGE

  • 15

    ? method: Calcium salts = black

    Von Kossa’s silver nitrate

  • 16

    Von Kossa’s silver nitrate method: ? = black

    Calcium salts

  • 17

    Von Kossa’s silver nitrate method: Calcium salts = ?

    black

  • 18

    Red chromogen for peroxidases:

    Aminoethylcarbazole (AEC)

  • 19

    Brown chromogen for peroxidases:

    Diaminobenzidine (DAB)

  • 20

    ?color chromogen for peroxidases: Diaminobenzidine (DAB)

    Brown

  • 21

    ? color chromogen for peroxidases: Aminoethylcarbazole (AEC)

    Red

  • 22

    Administrative investigation:

    2 members of board + 1 legal officer

  • 23

    Policies and guidelines for Med Tech Education:

    CMO no. 14 s. 2006

  • 24

    Accreditation of clinical lab for training MT interns:

    CMO no. 6 s. 2008

  • 25

    STAT, STATIM:

    Immediately

  • 26

    : Immediately

    STAT, STATIM

  • 27

    Biodegradable wastes: color bag

    Green bag

  • 28

    ? wastes: Green bag

    Biodegradable

  • 29

    Urine for routine urinalysis: ? ml urine (? capacity)

    10 to 15 ( 50 mlcontainer capacity)

  • 30

    Urine for drug testing: ? ml (?-container capacity)

    30 to 45 , (60 ml-container capacity)

  • 31

    Urine for cytology: ? ml urine (Gregorios)

    at least 50

  • 32

    Venipucture: ? degree angle

    15 to 30 degree angle

  • 33

    Arterial puncture: ? degree angle (90 degrees for femoral artery)

    45 to 60

  • 34

    Arterial puncture: 45 to 60 degree angle (90 degrees for ?)

    femoral artery

  • 35

    Arterial puncture: 45 to 60 degree angle (? degrees for femoral artery)

    90

  • 36

    ?: 45 to 60 degree angle (90 degrees for femoral artery)

    Arterial puncture

  • 37

    : 15 to 30 degree angle

    Venipucture

  • 38

    Before blood is collected from the radial artery in the wrist, one should do a ? to determine whether the ulnar artery can provide collateral circulation to the hand after the radial artery puncture

    MODIFIED ALLEN TEST

  • 39

    ? collection: eliminates multiple phlebotomies and surgical situations

    Central Venous Assess (CVA)

  • 40

    ) ml of blood must be drawn and discarded to eliminate contaminants

    Five (5

  • 41

    is not recommended for bacteriology (organisms can contaminate specimen)

    CVA

  • 42

    Order of draw from CATHETER LINES: First ? ml blood is discarded THEN, blood culture, anticoagulated tubes and clot tubes.

    3 to 5

  • 43

    Donor bleeding: ? degree angle to the skin, make a quick clean puncture; once in the skin, reduce the angle of the needle to about 10 to 20 degrees

    45 degree angle

  • 44

    Donor bleeding: 45 degree angle to the skin, make a quick clean puncture; once in the skin, reduce the angle of the needle to about ?degrees

    10 to 20

  • 45

    Anaerobic and require ICE slurry (immediate cooling):

    Lactic acid, ammonia, blood gas

  • 46

    Anaerobic and require ICE slurry (immediate cooling): Lactic acid, ammonia, blood gas (if not analyzed within ? min = ↓ pH, and po2),

    30

  • 47

    Anaerobic and require ICE slurry (immediate cooling): Lactic acid, ammonia, blood gas (if not analyzed within 30 min = pH, and po2),

  • 48

    (heparinized whole blood if not analyzed within 30 min)

    iCa+2

  • 49

    : evaluates hypoglycemia and continuous assessment of beta cell function

    C-Peptide test

  • 50

    Increased C-peptide:

    Insulinoma, type 2 DM, ingestion of hypoglycemic drugs

  • 51

    ? C-peptide: Insulinoma, type 2 DM, ingestion of hypoglycemic drugs

    Increased

  • 52

    Decreased C-peptide:

    Type 1 DM

  • 53

    ? C-peptide: Type 1 DM

    Decreased

  • 54

    Colorimetric method for Triglycerides:

    van Handel and Zilversmith

  • 55

    Colorimetric method for ?: van Handel and Zilversmith

    Triglycerides

  • 56

    CDC reference method:

    Modified van Handel and Zilversmith

  • 57

    ? method for Triglycerides: Hantzch condensation

    Fluorometric

  • 58

    Fluorometric method for ?: Hantzch condensation

    Triglycerides

  • 59

    Fluorometric method for Triglycerides:

    Hantzch condensation

  • 60

    Largest and least dense:

    CHYLOMICRONS

  • 61

    Smallest but the most dense:

    HDL

  • 62

    Found in obstructive jaundice and LCAT deficiency:

    Lipoprotein X

  • 63

    Found in ?and ? deficiency: Lipoprotein X

    obstructive jaundice and LCAT deficiency

  • 64

    Floating beta lipoprotein:

    β-VLDL

  • 65

    ? beta lipoprotein: β-VLDL

    Floating

  • 66

    Sinking pre-beta lipoprotein:

    Lp (a)

  • 67

    ? lipoprotein: Lp (a)

    Sinking pre-beta

  • 68

    Triglycerides, LDLc: FASTING

    12 to 14 hours

  • 69

    : FASTING 12 to 14 hours

    Triglycerides, LDLc

  • 70

    Formula for LDLc:

    Total cholesterol – HDL – VLDL

  • 71

    Friedewald VLDLc (mmol/L):

    Triglycerides/2.175

  • 72

    De Long VLDLc (mmol/L):

    Triglycerides/2.825

  • 73

    Friedewald VLDLc (mg/dL):

    Triglycerides/5

  • 74

    De Long VLDLc (mg/dL):

    Triglycerides/6.5

  • 75

    ONE-STEP direct method for cholesterol:

    LIEBERMANN-BURCHARDT (L-B)

  • 76

    One-step method for cholesterol: Colorimetry (?)

    Pearson, Stern and MacGavack

  • 77

    Two-step method for cholesterol: C + Extraction (?)

    Bloors

  • 78

    Three-step method for cholesterol: C+ E + Saponification (?)

    Abell-Kendall

  • 79

    Four-step method for cholesterol: C + E + S + Precipitation (?)

    Schoenheimer, Sperry, Parekh and Jung

  • 80

    CDC reference method for cholesterol:

    Abell, Levy and Brodie method

  • 81

    Modification of the ? method continues as the REFERENCE METHOD for cholesterol used by the CDC (Henry)

    ABELL-KENDALL

  • 82

    Modification of the ABELL-KENDALL method continues as the ? METHOD for cholesterol used by the CDC (Henry)

    REFERENCE

  • 83

    Modification of the ABELL-KENDALL method continues as the REFERENCE METHOD for cholesterol used by the ? (Henry)

    CDC

  • 84

    : HDL is abnormal and significantly reduced

    TANGIER’S DISEASE

  • 85

    Activated at cold temperature:

    Factors VII and XI (seven, eleven)

  • 86

    Labile factors, decrease on storage:

    Factors V and VIII (five, eight

  • 87

    ? tube: 11.5 cm long, 3 mm bore

    Wintrobe

  • 88

    Wintrobe tube: ? cm long, ? mm bore

    11.5 cm long, 3 mm bore

  • 89

    Westergren tube: ? cm long, 2.5 mm bore

    30

  • 90

    Westergren tube: 30 cm long, ? mm bore

    2.5

  • 91

    ? tube: 30 cm long, 2.5 mm bore

    Westergren

  • 92

    Capillary tube: ? cm (70-75 mm) long, 1 mm bore (1.2 mm)

    7 to 7.5

  • 93

    Capillary tube: 7 to 7.5 cm (?mm) long, 1 mm bore (1.2 mm)

    70-75

  • 94

    Capillary tube: 7 to 7.5 cm (70-75 mm) long, ? mm bore (? mm)

    1, 1.2

  • 95

    : Centrifuge at 2,000 to 2,300 g for 30 minutes

    Macrohematocrit

  • 96

    Macrohematocrit: Centrifuge at

    2,000 to 2,300 g for 30 minutes

  • 97

    : Centrifuge at 10,000 to 15,000 g for 5 minutes (five minutes)

    Microhematocrit

  • 98

    Microhematocrit: Centrifuge at

    10,000 to 15,000 g for 5 minutes (five minutes)

  • 99

    Normocytic, normochromic:

    GSARAP G6PD SICKLE CELL ANEMIA ACUTE BLOOD LOSS/ LEUKEMIA RENAL DSE APLASTIC ANEMIA PURE RED CELL ANEMIA

  • 100

    GSARAP G6PD SICKLE CELL ANEMIA ACUTE BLOOD LOSS/ LEUKEMIA RENAL DSE APLASTIC ANEMIA PURE RED CELL ANEMIA

    Normocytic, normochromic: